Evaluating the Relationship Between Metabolic Syndrome and Liver Biopsy-Proven Non-Alcoholic Steatohepatitis in China: A Multicenter Cross-Sectional Study Design
详细信息 查看全文
- 作者：Zheng-Jie Xu ; Jun-Ping Shi ; De-Rong Yu ; Li-Juan Zhu ; Ji-Dong Jia…
- 关键词：Diagnosis ; Gastroenterology ; Liver biopsy ; Metabolic syndrome ; Non ; alcoholic fatty liver disease ; Non ; alcoholic steatohepatitis
- 刊名：Advances in Therapy
- 出版年：2016
- 出版时间：November 2016
- 年：2016
- 卷：33
- 期：11
- 页码：2069-2081
- 全文大小：645 KB
- 刊物主题：Internal Medicine; Oncology; Cardiology; Rheumatology; Endocrinology; Pharmacology/Toxicology;
- 出版者：Springer Healthcare
- ISSN：1865-8652
- 卷排序：33
文摘
IntroductionNon-alcoholic steatohepatitis (NASH) is a serious form of non-alcoholic fatty liver disease (NAFLD) that can progress to advanced fibrosis, cirrhosis, and hepatocellular carcinoma. Differentiating between non-alcoholic fatty liver (NAFL) and NASH/advanced fibrosis is an important step in the management of NAFLD. Metabolic syndrome (MS) and its components are important risk factors for NAFLD, and NASH is thought to be the hepatic injury of MS. The prevalence of NASH among NAFLD patients with MS is thought to be high. In China, NAFLD is a relatively new public health concern, and the current prevalence of NASH among Chinese liver biopsy-proven NAFLD patients with and without MS is not known.